Ireland Relaxes Stance On Biosimilar Switching
But The National Biosimilars Policy Is Still Awaited
Executive Summary
The Irish medicines regulator, the HPRA, is proposing to revamp its guidance on biosimilar medicines and to take a more flexible attitude to biosimilar interchangeability and switching. The guidance is expected to feed into a future national biosimilars policy.
You may also be interested in...
Ireland Drops Cautionary Stance On Repeated Biosimilar Switching
Ireland’s Health Products Regulatory Authority has updated its 2015 biosimilars guideline for healthcare professionals. Since that time the use of biosimilars across the EU has grown considerably and more data on their use is available.
Ireland Drops Cautionary Stance On Repeated Biosimilar Switching
Ireland’s Health Products Regulatory Authority has updated its 2015 biosimilars guideline for healthcare professionals. Since that time the use of biosimilars across the EU has grown considerably and more data on their use is available.
Switching, Substitution & Quotas: Irish Govt Wants Views On Boosting Biosimilars
Stakeholders are being asked to respond to a consultation on what steps can be taken to increase the use of biosimilars in Ireland. The generics and biosimilars industry body Medicines for Ireland has welcomed the move but says it has come very late in the day.